Published in N Engl J Med on November 11, 2014
Hepatitis C. Lancet (2015) 1.95
Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network. Liver Transpl (2016) 1.67
Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology (2016) 1.52
Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection. AIDS (2016) 1.45
KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2016) 1.15
Changes in Utilization and Discard of Hepatitis C-Infected Donor Livers in the Recent Era. Am J Transplant (2016) 1.11
Treatment Options in Hepatitis C. Dtsch Arztebl Int (2017) 1.10
Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy. Clin Pharmacokinet (2016) 0.99
Advances in hepatitis C therapy: What is the current state - what come's next? World J Hepatol (2016) 0.98
APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int (2016) 0.96
Enhancing our understanding of current therapies for hepatitis C virus (HCV). Curr HIV/AIDS Rep (2015) 0.94
New perspectives for preventing hepatitis C virus liver graft infection. Lancet Infect Dis (2016) 0.91
Beyond the NIH Multicenter HIV Transplant Trial Experience: Outcomes of HIV+ Liver Transplant Recipients Compared to HCV+ or HIV+/HCV+ Coinfected Recipients in the United States. Clin Infect Dis (2015) 0.90
New approaches in the treatment of hepatitis C. World J Gastroenterol (2016) 0.90
Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients? Clin Gastroenterol Hepatol (2015) 0.88
New Direct-Acting Antiviral Therapies for Treatment of Chronic Hepatitis C Virus Infection. Gastroenterol Hepatol (N Y) (2015) 0.86
Management of Hepatitis C Post-liver Transplantation: a Comprehensive Review. J Clin Transl Hepatol (2015) 0.86
SASLT guidelines: Update in treatment of Hepatitis C virus infection. Saudi J Gastroenterol (2016) 0.85
Keys to long-term care of the liver transplant recipient. Nat Rev Gastroenterol Hepatol (2015) 0.83
Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for chronic hepatitis C. Aust Prescr (2016) 0.83
Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance. Viruses (2015) 0.82
Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation. Liver Transpl (2016) 0.80
Liver transplantation for viral hepatitis in 2015. World J Gastroenterol (2016) 0.80
Treatment of Hepatitis C Virus Infection in Liver Transplant Recipients. Gastroenterol Hepatol (N Y) (2016) 0.80
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. Ann Intern Med (2017) 0.79
Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future? PLoS One (2015) 0.79
APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatol Int (2016) 0.79
Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection. World J Gastroenterol (2016) 0.78
Pharmaceutical management of hepatitis B and C in liver and kidney transplant recipients. World J Gastrointest Pharmacol Ther (2015) 0.78
Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection. Drug Des Devel Ther (2015) 0.78
Acute Rejection Increases Risk of Graft Failure and Death in Recent Liver Transplant Recipients. Clin Gastroenterol Hepatol (2016) 0.77
Impact of new treatment options for hepatitis C virus infection in liver transplantation. World J Gastroenterol (2015) 0.77
Chronic Kidney Disease and Related Long-Term Complications After Liver Transplantation. Adv Chronic Kidney Dis (2015) 0.77
Era of direct acting antivirals in chronic hepatitis C: Who will benefit? World J Hepatol (2015) 0.76
Paritaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise review. Hepat Med (2016) 0.76
Hepatitis C virus-HIV-coinfected patients and liver transplantation. Curr Opin Organ Transplant (2015) 0.76
Antiviral treatment prioritization in HCV-infected patients with extrahepatic manifestations - An Egyptian perspective. J Adv Res (2016) 0.76
Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease. F1000Res (2016) 0.76
Hepatitis C Virus and Liver Transplantation. Gastroenterol Hepatol (N Y) (2017) 0.75
Combination ledipasvir-sofosbuvir for the treatment of chronic hepatitis C virus infection: a review and clinical perspective. Ther Clin Risk Manag (2016) 0.75
A bridge between multi-omics data and the management of hepatocellular carcinoma. Ann Transl Med (2015) 0.75
An HCV-positive recipient of an HCV-positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin. Clin Case Rep (2017) 0.75
Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials. Br J Clin Pharmacol (2016) 0.75
Two-Year Follow-Up Analysis of Telaprevir-Based Antiviral Triple Therapy for HCV Recurrence in Genotype 1 Infected Liver Graft Recipients as a First Step towards Modern HCV Therapy. Hepat Res Treat (2016) 0.75
Hepatitis: treating HCV after liver transplant. Nat Rev Gastroenterol Hepatol (2014) 0.75
Is it time to rethink combined liver-kidney transplant in hepatitis C patients with advanced fibrosis? World J Hepatol (2017) 0.75
Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus. World J Gastroenterol (2016) 0.75
Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection. Liver Int (2016) 0.75
Pre- and Post-Transplant Antiviral Therapy (HBV, HCV). Visc Med (2016) 0.75
Donor Factors Including Donor Risk Index Predict Fibrosis Progression, Allograft Loss, and Patient Survival following Liver Transplantation for Hepatitis C Virus. J Clin Exp Hepatol (2015) 0.75
Use of Hepatitis C-Positive Donor Livers in Liver Transplantation. Curr Hepatol Rep (2017) 0.75
Sofosbuvir and Simeprevir Therapy for Recurrent Hepatitis C Infection After Liver Transplantation. Transplant Direct (2015) 0.75
Current Issues in Liver Transplantation. Gastroenterol Hepatol (N Y) (2016) 0.75
Brief Report: Significant Decreases in Both Total and Unbound Lopinavir and Amprenavir Exposures During Coadministration: ACTG Protocol A5143/A5147s Results. J Acquir Immune Defic Syndr (2015) 0.75
Indications for liver transplantation in adults : Recommendations of the Austrian Society for Gastroenterology and Hepatology (ÖGGH) in cooperation with the Austrian Society for Transplantation, Transfusion and Genetics (ATX). Wien Klin Wochenschr (2016) 0.75
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir. Hosp Pharm (2015) 0.75
Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection. J Clin Transl Hepatol (2016) 0.75
Sofosbuvir and ribavirin before liver re-transplantation for graft failure due to recurrent hepatitis C: a case report. BMC Gastroenterol (2015) 0.75
Curing Hepatitis C in Liver Transplant Recipients Is Associated with Changes in Immunosuppressant Use. J Clin Transl Hepatol (2016) 0.75
Treatment of Hepatitis C in Patients Undergoing Immunosuppressive Drug Therapy. J Clin Transl Hepatol (2016) 0.75
Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence. World J Gastroenterol (2016) 0.75
Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection. PLoS One (2016) 0.75
Hepatitis C in Liver Allograft Recipients: Utility of One-Year Post-Transplantation Biopsy as an Indicator of Antiviral Therapy. Gastroenterology Res (2015) 0.75
Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand? World J Hepatol (2015) 0.75
Bilateral simultaneous anterior ischemic optic neuropathy, an extrahepatic manifestation of hepatitis C cured with direct acting antivirals. GMS Ophthalmol Cases (2016) 0.75
When and How to Treat HCV Infection with the New Antivirals before or after Liver Transplantation. Visc Med (2016) 0.75
HCV cure for everyone or which challenges remain? J Virus Erad (2015) 0.75
Organ Transplantation in the Face of Donor Shortage - Ethical Implications with a Focus on Liver Allocation. Visc Med (2016) 0.75
Potential Liver Transplant Recipients with Hepatitis C: Should They Be Treated Before or After Transplantation? J Clin Exp Hepatol (2017) 0.75
Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C. J Clin Transl Hepatol (2017) 0.75
Direct-acting antiviral agent efficacy and safety in renal transplant recipients with chronic hepatitis C virus infection: A PRISMA-compliant study. Medicine (Baltimore) (2017) 0.75
Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis. Clin Drug Investig (2017) 0.75
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res (2008) 8.17
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med (2014) 6.31
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med (2014) 5.29
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med (2014) 4.90
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology (2006) 4.90
Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med (2005) 4.27
Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol (2008) 4.21
Burden of liver disease in the United States: summary of a workshop. Hepatology (2002) 4.00
Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol (2007) 3.86
Noninvasive assessment of liver fibrosis. Hepatology (2010) 3.86
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis (2007) 3.75
Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med (2013) 3.52
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis (2010) 3.47
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med (2014) 3.40
Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS One (2009) 3.40
Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl (2006) 3.29
Hospital admission is a relevant source of hepatitis C virus acquisition in Spain. J Hepatol (2007) 3.21
Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology (2004) 3.19
Epigenome-wide association study in the European Prospective Investigation into Cancer and Nutrition (EPIC-Turin) identifies novel genetic loci associated with smoking. Hum Mol Genet (2012) 3.07
HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis (2007) 3.05
Comparison of plethysmographic and helium dilution lung volumes: which is best for COPD? Chest (2009) 2.98
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int (2011) 2.77
Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology (2005) 2.63
Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. J Hepatol (2008) 2.63
Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl (2005) 2.63
Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology (2006) 2.62
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med (2014) 2.54
Case scenario: acute postoperative negative pressure pulmonary edema. Anesthesiology (2010) 2.54
Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol (2007) 2.48
Health risk of chrysotile revisited. Crit Rev Toxicol (2013) 2.45
DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst (2005) 2.43
Second hepatitis C replication compartment indicated by viral dynamics during liver transplantation. J Hepatol (2005) 2.39
Herpes simplex virus hepatitis: an analysis of the published literature and institutional cases. Liver Transpl (2007) 2.31
Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model. Cancer (2014) 2.26
Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology (2005) 2.24
An international multicenter performance analysis of cytomegalovirus load tests. Clin Infect Dis (2012) 2.20
Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology (2002) 2.15
CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res (2005) 2.11
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res (2011) 2.09
Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clin Cancer Res (2007) 2.08
Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology (2007) 2.07
Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology (2006) 2.03
National survey of provider opinions on controversial characteristics of liver transplant candidates. Liver Transpl (2013) 2.00
A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med (2007) 1.99
Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol Ther (2011) 1.96
The probable source of both the primary multidrug-resistant (MDR) HIV-1 strain found in a patient with rapid progression to AIDS and a second recombinant MDR strain found in a chronically HIV-1-infected patient. J Infect Dis (2007) 1.93
Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res (2002) 1.91
Esophageal capsule endoscopy for screening and surveillance of esophageal varices in patients with portal hypertension. Hepatology (2008) 1.91
Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology (2014) 1.91
The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant (2005) 1.90
A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res (2008) 1.89
Thrombocytopenia associated with chronic liver disease. J Hepatol (2008) 1.89
Asthma outcomes: biomarkers. J Allergy Clin Immunol (2012) 1.88
Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther (2003) 1.87
Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology. Hepatology (2007) 1.86
PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl (2011) 1.85
In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J Virol (2008) 1.84
miRNA malfunction causes spinal motor neuron disease. Proc Natl Acad Sci U S A (2010) 1.83
Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection associated with viral persistence. Hepatology (2006) 1.78
Signalling cell cycle arrest and cell death through the MMR System. Carcinogenesis (2005) 1.77
Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro. Antimicrob Agents Chemother (2005) 1.75
CpG island methylator phenotype (CIMP) in cancer: causes and implications. Cancer Lett (2008) 1.75
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun (2013) 1.73
Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther (2011) 1.70
Thromboembolic complications after surgical correction of mitral regurgitation incidence, predictors, and clinical implications. J Am Coll Cardiol (2008) 1.66
Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol (2005) 1.66
Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology (2004) 1.65
The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res (2004) 1.65
Serum phosphorus levels predict clinical outcome in fulminant hepatic failure. Liver Transpl (2003) 1.64
Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1. Gut (2012) 1.63
Assessment of chronic hepatitis and fibrosis: comparison of MR elastography and diffusion-weighted imaging. AJR Am J Roentgenol (2011) 1.62
ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecol Oncol (2013) 1.61
Ghrelin attenuates hepatocellular injury and liver fibrogenesis in rodents and influences fibrosis progression in humans. Hepatology (2010) 1.61
Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211. J Infect Dis (2009) 1.61
Laboratory test results after living liver donation in the adult-to-adult living donor liver transplantation cohort study. Liver Transpl (2011) 1.59
Viral hepatitis in liver transplantation. Gastroenterology (2012) 1.59
Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response. Am J Gastroenterol (2010) 1.59
Liver transplantation for hepatocellular carcinoma: the MELD impact. Liver Transpl (2004) 1.58
The dynamics of herpesvirus and polyomavirus reactivation and shedding in healthy adults: a 14-month longitudinal study. J Infect Dis (2003) 1.57
Alcohol use and hepatitis C. Hepatology (2002) 1.55
Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA). J Clin Microbiol (2004) 1.55
Hepatitis C virus receptors claudin-1 and occludin after liver transplantation and influence on early viral kinetics. Hepatology (2011) 1.54
Recipient-donor race mismatch for African American liver transplant patients with chronic hepatitis C. Liver Transpl (2012) 1.54
Retransplantation for hepatitis C: results of a U.S. multicenter retransplant study. Liver Transpl (2007) 1.54
Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation (2003) 1.54
Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res (2006) 1.53
Lymphoproliferative disorders in Costa Rica and simian virus 40. Haematologica (2005) 1.53
Specific and quantitative detection of human polyomaviruses BKV, JCV, and SV40 by real time PCR. J Clin Virol (2005) 1.53
Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus. Liver Transpl (2011) 1.52
Ethnic differences in polyomavirus simian virus 40 seroprevalence among women in Houston, Texas. J Infect (2012) 1.52
Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk. Cancer Res (2012) 1.52
A case of adult hepatic toxocariasis. Nat Clin Pract Gastroenterol Hepatol (2008) 1.51
Comparative effectiveness of liver transplant strategies for end-stage liver disease patients on renal replacement therapy. Liver Transpl (2014) 1.50
Determination of IL28B polymorphisms in liver biopsies obtained after liver transplantation. J Hepatol (2011) 1.50